EP1446162A4 - Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung - Google Patents
Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkungInfo
- Publication number
- EP1446162A4 EP1446162A4 EP02768621A EP02768621A EP1446162A4 EP 1446162 A4 EP1446162 A4 EP 1446162A4 EP 02768621 A EP02768621 A EP 02768621A EP 02768621 A EP02768621 A EP 02768621A EP 1446162 A4 EP1446162 A4 EP 1446162A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- nucleic acids
- increased activity
- immunostimulatory oligonucleotides
- combined pattern
- class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003308 immunostimulating effect Effects 0.000 title abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200230776T SI1446162T1 (sl) | 2001-08-17 | 2002-08-19 | Kombinacija zaporedja imunostimulatornih oligonukleotidov z izboljšano aktivnostjo |
| CY20081101400T CY1109398T1 (el) | 2001-08-17 | 2008-12-03 | Ανοσοδιεγερτικα ολιγονουκλεοτιδια συνδυαστικου μοτιβου με βελτιωμενη δραστικοτητα |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31327301P | 2001-08-17 | 2001-08-17 | |
| US313273P | 2001-08-17 | ||
| US39395202P | 2002-07-03 | 2002-07-03 | |
| US393952P | 2002-07-03 | ||
| PCT/US2002/026468 WO2003015711A2 (en) | 2001-08-17 | 2002-08-19 | Combination motif immune stimulatory oligonucleotides with improved activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP1446162A2 EP1446162A2 (de) | 2004-08-18 |
| EP1446162A4 true EP1446162A4 (de) | 2005-02-16 |
| EP1446162B1 EP1446162B1 (de) | 2008-10-15 |
Family
ID=26978772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02768621A Expired - Lifetime EP1446162B1 (de) | 2001-08-17 | 2002-08-19 | Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8834900B2 (de) |
| EP (1) | EP1446162B1 (de) |
| JP (2) | JP4383534B2 (de) |
| KR (1) | KR100991644B1 (de) |
| CN (1) | CN1604795B (de) |
| AT (1) | ATE411054T1 (de) |
| AU (1) | AU2002331643B2 (de) |
| BR (1) | BR0211962A (de) |
| CA (1) | CA2457485C (de) |
| CY (1) | CY1109398T1 (de) |
| DE (1) | DE60229422D1 (de) |
| DK (1) | DK1446162T3 (de) |
| EA (1) | EA007232B1 (de) |
| ES (1) | ES2314099T3 (de) |
| IL (2) | IL160157A0 (de) |
| MX (1) | MXPA04001458A (de) |
| NZ (2) | NZ552377A (de) |
| PT (1) | PT1446162E (de) |
| SG (1) | SG177000A1 (de) |
| SI (1) | SI1446162T1 (de) |
| WO (1) | WO2003015711A2 (de) |
| ZA (1) | ZA200401531B (de) |
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| EP0855184A1 (de) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| AU760549B2 (en) * | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| SI1077722T1 (sl) | 1998-05-22 | 2007-02-28 | Ottawa Health Research Inst | Metode in produkti za induciranje sluznicne imunosti |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| ES2572834T3 (es) | 1999-02-17 | 2016-06-02 | Csl Limited | Complejos inmunogénicos y métodos relacionados con los mismos |
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| NZ517929A (en) * | 1999-09-25 | 2004-02-27 | Univ Iowa Res Found | Immunostimulatory nucleic acids |
| US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| AU2001227889A1 (en) | 2000-01-14 | 2001-07-24 | The United States of America, represented by The Secretary, Department of Health & Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| US20010044416A1 (en) * | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
| US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| EP1296714B1 (de) * | 2000-06-22 | 2009-08-26 | University Of Iowa Research Foundation | Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs. |
| JP2005500806A (ja) * | 2000-09-15 | 2005-01-13 | コーリー ファーマシューティカル ゲーエムベーハー | ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス |
| ES2307568T3 (es) * | 2000-12-08 | 2008-12-01 | Coley Pharmaceutical Gmbh | Acidos nucleicos de tipo cpg y metodos de uso de los mismos. |
| KR100881923B1 (ko) | 2000-12-27 | 2009-02-04 | 다이나박스 테크놀로지 코퍼레이션 | 면역자극 폴리뉴클레오티드 및 그것의 사용 방법 |
| EP2423335B1 (de) * | 2001-06-21 | 2014-05-14 | Dynavax Technologies Corporation | Chimäre immunmodulierende Verbindungen und Verwendungsverfahren dafür |
| US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
| WO2003020884A2 (en) | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| ATE411054T1 (de) | 2001-08-17 | 2008-10-15 | Coley Pharm Gmbh | Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung |
| CN1633598A (zh) * | 2001-10-05 | 2005-06-29 | 科勒制药股份公司 | Toll样受体3信号传导的激动剂和拮抗剂 |
| US20030139364A1 (en) * | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
| WO2003054161A2 (en) | 2001-12-20 | 2003-07-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
| US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
| EP3006043B1 (de) | 2002-04-04 | 2019-05-29 | Zoetis Belgium S.A. | Immunostimulatorische g,u-haltige oligoribonucleotide |
| US20040009949A1 (en) * | 2002-06-05 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids |
| US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| WO2004005476A2 (en) * | 2002-07-03 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| WO2004007743A2 (en) * | 2002-07-17 | 2004-01-22 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
| AR040996A1 (es) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| US8263091B2 (en) | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
| CN1753687A (zh) * | 2002-10-29 | 2006-03-29 | 科勒制药集团股份有限公司 | Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用 |
| CA2502015A1 (en) | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5' cpg nucleic acids and methods of use |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| JP5102959B2 (ja) * | 2002-12-23 | 2012-12-19 | ダイナバックス テクノロジーズ コーポレイション | 免疫刺激配列オリゴヌクレオチド及びその使用方法 |
| MXPA05013922A (es) * | 2003-06-20 | 2006-02-24 | Coley Pharm Group Inc | Antagonistas de receptor tipo toll de molecula pequena. |
| AU2004275876B2 (en) | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
| EP1678303A2 (de) * | 2003-10-30 | 2006-07-12 | Coley Pharmaceutical GmbH | C-klasse-oligonukleotidanaloge mit verbesserter immunstimulatorischer potency |
| US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
| US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
| US9090673B2 (en) * | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
| KR100558851B1 (ko) * | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체 |
| US20060287263A1 (en) * | 2004-07-18 | 2006-12-21 | Csl Limited | Methods and compositions for inducing antigen-specific immune responses |
| MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| AU2006241149A1 (en) * | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
| JP4538522B2 (ja) * | 2005-11-25 | 2010-09-08 | コーリー ファーマシューティカル ゲーエムベーハー | 免疫刺激性オリゴリボヌクレオチド |
| DK2405002T3 (en) | 2006-02-15 | 2015-01-05 | Adiutide Pharmaceuticals Gmbh | Compositions and methods for oligonukleotidformuleringer |
| CN101460620B (zh) | 2006-05-31 | 2012-02-15 | 东丽株式会社 | 免疫刺激寡核苷酸及其药物用途 |
| US20080026986A1 (en) * | 2006-06-05 | 2008-01-31 | Rong-Fu Wang | Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling |
| PT2078080E (pt) | 2006-09-27 | 2015-09-18 | Coley Pharm Gmbh | Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada |
| AU2007353120A1 (en) * | 2006-10-26 | 2008-11-20 | Coley Pharmaceutical Gmbh | Oligoribonucleotides and uses thereof |
| US20090142362A1 (en) * | 2006-11-06 | 2009-06-04 | Avant Immunotherapeutics, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP) |
| CA2687441A1 (en) | 2007-05-17 | 2008-11-27 | Coley Pharmaceutical Group, Inc. | Class a oligonucleotides with immunostimulatory potency |
| US9200287B2 (en) * | 2007-05-18 | 2015-12-01 | Adiutide Pharmaceuticals Gmbh | Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity |
| KR20100045508A (ko) | 2007-08-13 | 2010-05-03 | 콜리 파마슈티칼 게엠베하 | 특이적 면역 조절 프로필을 유도하는 규정된 뉴클레오티드간 연결의 환경에서의 ｒｎａ 서열 모티프 |
| CA2696460A1 (en) * | 2007-08-13 | 2009-02-19 | Pfizer Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
| CN101820908A (zh) * | 2007-10-09 | 2010-09-01 | 科利制药公司 | 包含改性糖部分的免疫刺激寡核苷酸类似物 |
| ES2569907T3 (es) | 2008-06-27 | 2016-05-13 | Zoetis Services Llc | Composiciones adyuvantes novedosas |
| AU2009304552B2 (en) | 2008-10-16 | 2015-02-19 | Dalhousie University | Combination adjuvant formulation |
| CN102439149B (zh) * | 2009-02-12 | 2018-01-02 | 库尔纳公司 | 通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病 |
| CN103800906B (zh) | 2009-03-25 | 2017-09-22 | 德克萨斯大学系统董事会 | 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物 |
| US20120052088A1 (en) | 2009-04-30 | 2012-03-01 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
| EP2575878B1 (de) | 2010-05-28 | 2018-06-13 | Zoetis Belgium S.A. | Impstoffe mit cholesterin und cpg als einzige adjuvans-träger moleküle |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| EP2640426B1 (de) * | 2010-11-16 | 2016-02-03 | Selecta Biosciences, Inc. | Immunstimulierende oligonukleotide |
| EP2471926A3 (de) * | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunstimulierende Oligodeoxynukleotide |
| MX346596B (es) * | 2011-05-26 | 2017-03-23 | Intervet Int Bv | Oligodesoxinucleotidos inmunoestimuladores. |
| CA2837227C (en) | 2011-06-01 | 2022-05-10 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| WO2012167053A1 (en) | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| CA2850932A1 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
| US12268718B2 (en) | 2012-01-16 | 2025-04-08 | Labyrinth Holdings Llc | Control of cellular redox levels |
| CA3208225A1 (en) | 2012-01-16 | 2013-07-25 | Elizabeth Mckenna | Compositions and methods for the treatment of hepatitic diseases and disorders |
| JP2014012650A (ja) * | 2012-07-05 | 2014-01-23 | Nihon Univ | 上皮バリア機能の増強方法及び増強剤 |
| CA2879066C (en) | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| JP2015535829A (ja) | 2012-09-21 | 2015-12-17 | マッケーナ、エリザベス | 天然に存在するＣｐＧオリゴヌクレオチド組成物およびその治療的適用 |
| UA130246C2 (uk) | 2013-09-19 | 2025-12-31 | Зоетіс Сервісіз Ллс | Ад'ювант на основі олії |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| EP3183251A4 (de) | 2014-08-22 | 2017-12-27 | Janus Biotherapeutics, Inc. | Neuartige n2,n4,n7,6-tetrasubstituerte pteridin-2,4,7-triamin- und 2,4,6,7-ted pteridin-verbindungen und verfahren zur synthese und verwendung davon |
| WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
| PL3240801T3 (pl) | 2014-12-31 | 2021-06-14 | Checkmate Pharmaceuticals, Inc. | Skojarzona immunoterapia nowotworów |
| CN115317600A (zh) | 2015-01-16 | 2022-11-11 | 硕腾服务有限责任公司 | 口蹄疫疫苗 |
| WO2017011919A1 (en) | 2015-07-22 | 2017-01-26 | University Of Saskatchewan | Mycoplasma vaccines and uses thereof |
| WO2017173334A1 (en) | 2016-04-01 | 2017-10-05 | Checkmate Pharmaceuticals, Inc. | Fc receptor-mediated drug delivery |
| US11173207B2 (en) | 2016-05-19 | 2021-11-16 | The Regents Of The University Of Michigan | Adjuvant compositions |
| WO2018141810A1 (en) * | 2017-01-31 | 2018-08-09 | Alf Lamprecht | Use of nanoparticles for immunotherapy |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019160866A2 (en) | 2018-02-13 | 2019-08-22 | Checkmate Pharmaceuticals, Inc. | Compositions and methods for tumor immunotherapy |
| BR112020020479A2 (pt) | 2018-04-09 | 2021-01-12 | Checkmate Pharmaceuticals | Empacotamento de oligonucleotídeos em partículas similares a vírus |
| KR102602329B1 (ko) | 2018-05-23 | 2023-11-16 | 화이자 인코포레이티드 | Cd3에 특이적인 항체 및 이의 용도 |
| MX2020012607A (es) | 2018-05-23 | 2021-01-29 | Pfizer | Anticuerpos especificos para gucy2c y sus usos. |
| US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
| CA3131701A1 (en) | 2019-02-28 | 2020-09-03 | Sqz Biotechnologies Company | Delivery of biomolecules to pbmcs to modify an immune response |
| CA3164623A1 (en) | 2019-12-17 | 2021-06-24 | Pfizer Inc. | Antibodies specific for cd47, pd-l1, and uses thereof |
| BR112022021258A2 (pt) | 2020-04-20 | 2023-01-17 | Univ Saskatchewan | Composições e métodos para prevenir, controlar e diagnosticar infecções micobacterianas |
| EP4559477A3 (de) | 2020-05-13 | 2025-08-13 | Adagene AG | Zusammensetzungen und verfahren zur behandlung von krebs |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| JP2024534858A (ja) * | 2021-08-31 | 2024-09-26 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | インターフェロン誘導性の複合体およびｒｎａ二重鎖ならびに使用方法 |
| KR102730717B1 (ko) * | 2021-09-02 | 2024-11-14 | 세종대학교산학협력단 | 미토콘드리아 dna 매개 면역 증강 유도용 구아닌/시토신 기반 포스포로티오에이트 결합 줄기-고리 구조 올리고데옥시뉴클레오타이드 |
| US20250346649A1 (en) | 2021-11-05 | 2025-11-13 | St. Jude Children's Research Hospital, Inc. | Zip cytokine receptors |
| US20250312450A1 (en) | 2022-06-08 | 2025-10-09 | St. Jude Children's Research Hospital, Inc. | Disruption of kdm4a in t cells to enhance immunotherapy |
| US20260091115A1 (en) | 2022-09-16 | 2026-04-02 | St. Jude Children's Research Hospital, Inc. | Disruption of asxl1 in t cells to enhance immunotherapy |
| WO2025015118A1 (en) * | 2023-07-11 | 2025-01-16 | Rutgers, The State University Of New Jersey | Pharmaceutical compositions and methods for treating fungal infections |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001055370A2 (en) * | 2000-01-26 | 2001-08-02 | Hybridon, Inc. | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
Family Cites Families (157)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US384480A (en) * | 1888-06-12 | Signor to the faebweeke | ||
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| DE3280400D1 (de) | 1981-10-23 | 1992-06-04 | Molecular Biosystems Inc | Oligonukleotides heilmittel und dessen herstellungsverfahren. |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4806463A (en) | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
| US5194428A (en) | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
| US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| CA1339596C (en) | 1987-08-07 | 1997-12-23 | New England Medical Center Hospitals, Inc. | Viral expression inhibitors |
| US5004810A (en) | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5457189A (en) | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
| US5514788A (en) | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
| US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5514577A (en) | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
| US5248670A (en) | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
| US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| JPH04352724A (ja) * | 1990-07-27 | 1992-12-07 | Mitsui Toatsu Chem Inc | 免疫調節型治療剤 |
| ES2104717T3 (es) | 1990-08-16 | 1997-10-16 | Isis Pharmaceuticals Inc | Oligonucleotidos para modular los efectos de las infecciones por citomegalovirus. |
| WO1994008003A1 (en) | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
| US5582986A (en) | 1991-06-14 | 1996-12-10 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of the ras gene |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US6498147B2 (en) | 1992-05-22 | 2002-12-24 | The Scripps Research Institute | Suppression of nuclear factor-κb dependent processes using oligonucleotides |
| PL172710B1 (pl) | 1992-07-02 | 1997-11-28 | Hybridon Inc | Samostabilizujacy sie oligonukleotyd PL PL |
| DK0664833T3 (da) | 1992-10-05 | 1997-04-14 | Hybridon Inc | Terapeutisk anti-HIV oligonukletid og lægemiddel |
| US5567604A (en) | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
| KR960703170A (ko) | 1993-06-23 | 1996-06-19 | 알버트 디. 프리센. | 안티센스 올리고뉴클레오티드 및 인간면역결핍바이러스감염에서 그것의 치료적이용(antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection) |
| AU688364B2 (en) | 1993-07-19 | 1998-03-12 | Gen-Probe Incorporated | Oligonucleotides with activity against human immunodeficiency virus |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP1167379A3 (de) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatorische Oligonukleotide |
| US20030050263A1 (en) | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
| US5932556A (en) | 1995-09-17 | 1999-08-03 | Tam; Robert C | Methods and compositions for regulation of CD28 expression |
| GB9505438D0 (en) | 1995-03-17 | 1995-05-03 | Sod Conseils Rech Applic | Antisense oligonucleotides |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
| US6030955A (en) | 1996-03-21 | 2000-02-29 | The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. | Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof |
| ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
| EP0968226A4 (de) | 1996-12-27 | 2001-02-14 | Icn Pharmaceuticals | Oligoaptamere mit g-angereicherten regionen und methoden zur modulation einer immunantwort |
| EP0855184A1 (de) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung |
| US20030064945A1 (en) | 1997-01-31 | 2003-04-03 | Saghir Akhtar | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
| WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
| US6835395B1 (en) | 1997-05-14 | 2004-12-28 | The University Of British Columbia | Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles |
| WO1998052962A1 (en) | 1997-05-19 | 1998-11-26 | Merck & Co., Inc. | Oligonucleotide adjuvant |
| EP1003531B1 (de) * | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Verfahren zur Herstellung von Nukleinsäurekonstrukten |
| US20040006034A1 (en) | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| WO1999001154A1 (en) | 1997-07-03 | 1999-01-14 | University Of Iowa Research Foundation | Method for inhibiting immunostimulatory dna associated responses |
| US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
| JP4663113B2 (ja) | 1997-09-05 | 2011-03-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用 |
| US20050031638A1 (en) | 1997-12-24 | 2005-02-10 | Smithkline Beecham Biologicals S.A. | Vaccine |
| WO1999050297A1 (en) | 1998-03-27 | 1999-10-07 | Immunex Corporation | Nk cell activation inducing ligand (nail) dna and polypeptides, and use thereof |
| AU760549B2 (en) | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| CA2328602A1 (en) | 1998-05-06 | 1999-11-11 | University Of Iowa Research Foundation | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
| JP2002514397A (ja) | 1998-05-14 | 2002-05-21 | コーリー ファーマシューティカル ゲーエムベーハー | ＣｐＧオリゴヌクレオチドを用いる造血調節の方法 |
| SI1077722T1 (sl) | 1998-05-22 | 2007-02-28 | Ottawa Health Research Inst | Metode in produkti za induciranje sluznicne imunosti |
| US6881561B1 (en) | 1998-05-27 | 2005-04-19 | Cheil Jedang Corporation | Endonuclease of immune cell, process for producing the same and immune adjuvant using the same |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| WO1999063975A2 (en) | 1998-06-10 | 1999-12-16 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | A method for stimulating the immune system |
| US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
| JP2002521489A (ja) | 1998-07-27 | 2002-07-16 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法 |
| EP0979869A1 (de) | 1998-08-07 | 2000-02-16 | Hoechst Marion Roussel Deutschland GmbH | Kurze Oligonukleotide zur Hemmung von VEGF-Expression |
| WO2000014217A2 (en) | 1998-09-03 | 2000-03-16 | Coley Pharmaceutical Gmbh | G-motif oligonucleotides and uses thereof |
| US20020065236A1 (en) | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
| FR2783170B1 (fr) | 1998-09-11 | 2004-07-16 | Pasteur Merieux Serums Vacc | Emulsion immunostimulante |
| FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| EP1176966B1 (de) | 1999-04-12 | 2013-04-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oligodeoxynukleotide und deren verwendung zur induktion einer immunreaktion |
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
| EP1177439B1 (de) | 1999-04-29 | 2004-09-08 | Coley Pharmaceutical GmbH | Screening nach modulatoren der funktion von immunstimulatorischer dna |
| WO2000067787A2 (en) | 1999-05-06 | 2000-11-16 | The Immune Response Corporation | Hiv immunogenic compositions and methods |
| EP1196558A1 (de) | 1999-06-08 | 2002-04-17 | Aventis Pasteur | Immunostimulatorisches oligonukleotid |
| EP1377554A1 (de) | 1999-06-16 | 2004-01-07 | University Of Iowa Research Foundation | Antagonismus der immunostimulatorischen cpg-oligonukleotiden durch 4-aminochinolinen und sonstigen schwachen basen |
| US6514948B1 (en) | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
| DE19935756A1 (de) | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation |
| NZ517929A (en) | 1999-09-25 | 2004-02-27 | Univ Iowa Res Found | Immunostimulatory nucleic acids |
| AU783118B2 (en) | 1999-09-27 | 2005-09-29 | Coley Pharmaceutical Gmbh | Methods related to immunostimulatory nucleic acid-induced interferon |
| US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
| WO2001045750A1 (en) | 1999-12-21 | 2001-06-28 | The Regents Of The University Of California | Method for preventing an anaphylactic reaction |
| US20010044416A1 (en) | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
| US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| FR2805265B1 (fr) | 2000-02-18 | 2002-04-12 | Aventis Pasteur | Oligonucleotides immunostimulants |
| US20020156033A1 (en) | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
| US20040131628A1 (en) | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
| EP1296714B1 (de) | 2000-06-22 | 2009-08-26 | University Of Iowa Research Foundation | Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs. |
| US20020165178A1 (en) | 2000-06-28 | 2002-11-07 | Christian Schetter | Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia |
| US20020198165A1 (en) | 2000-08-01 | 2002-12-26 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of gastric ulcers |
| US20020091097A1 (en) | 2000-09-07 | 2002-07-11 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of sexually transmitted diseases |
| JP2005500806A (ja) | 2000-09-15 | 2005-01-13 | コーリー ファーマシューティカル ゲーエムベーハー | ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス |
| FR2814958B1 (fr) | 2000-10-06 | 2003-03-07 | Aventis Pasteur | Composition vaccinale |
| GB0025577D0 (en) | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
| ES2307568T3 (es) | 2000-12-08 | 2008-12-01 | Coley Pharmaceutical Gmbh | Acidos nucleicos de tipo cpg y metodos de uso de los mismos. |
| WO2002053141A2 (en) | 2000-12-14 | 2002-07-11 | Coley Pharmaceutical Group, Inc. | Inhibition of angiogenesis by nucleic acids |
| KR100881923B1 (ko) | 2000-12-27 | 2009-02-04 | 다이나박스 테크놀로지 코퍼레이션 | 면역자극 폴리뉴클레오티드 및 그것의 사용 방법 |
| US20030050268A1 (en) | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
| EP2423335B1 (de) | 2001-06-21 | 2014-05-14 | Dynavax Technologies Corporation | Chimäre immunmodulierende Verbindungen und Verwendungsverfahren dafür |
| US20030148316A1 (en) | 2001-08-01 | 2003-08-07 | Lipford Grayson B. | Methods and compositions relating to plasmacytoid dendritic cells |
| US20030133988A1 (en) | 2001-08-07 | 2003-07-17 | Fearon Karen L. | Immunomodulatory compositions, formulations, and methods for use thereof |
| ATE411054T1 (de) | 2001-08-17 | 2008-10-15 | Coley Pharm Gmbh | Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung |
| CN1633598A (zh) | 2001-10-05 | 2005-06-29 | 科勒制药股份公司 | Toll样受体3信号传导的激动剂和拮抗剂 |
| US20030139364A1 (en) | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
| US6838227B2 (en) * | 2001-11-30 | 2005-01-04 | Seagate Technology Llc | Polystyrene as a resist for making patterned media |
| EP3006043B1 (de) | 2002-04-04 | 2019-05-29 | Zoetis Belgium S.A. | Immunostimulatorische g,u-haltige oligoribonucleotide |
| US20040009949A1 (en) | 2002-06-05 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids |
| US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| WO2004007743A2 (en) | 2002-07-17 | 2004-01-22 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| AU2003278845A1 (en) | 2002-09-19 | 2004-04-08 | Coley Pharmaceutical Gmbh | Toll-like receptor 9 (tlr9) from various mammalian species |
| CN1753687A (zh) | 2002-10-29 | 2006-03-29 | 科勒制药集团股份有限公司 | Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用 |
| CA2502015A1 (en) | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5' cpg nucleic acids and methods of use |
| JP5102959B2 (ja) | 2002-12-23 | 2012-12-19 | ダイナバックス テクノロジーズ コーポレイション | 免疫刺激配列オリゴヌクレオチド及びその使用方法 |
| AU2004226605A1 (en) | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
| EP1631687A2 (de) | 2003-04-22 | 2006-03-08 | Coley Pharmaceutical GmbH | Verfahren und produkte zur identifizierung und beurteilung von tlr-liganden |
| MXPA05013922A (es) | 2003-06-20 | 2006-02-24 | Coley Pharm Group Inc | Antagonistas de receptor tipo toll de molecula pequena. |
| AU2004275876B2 (en) | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
| US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| EP1678303A2 (de) | 2003-10-30 | 2006-07-12 | Coley Pharmaceutical GmbH | C-klasse-oligonukleotidanaloge mit verbesserter immunstimulatorischer potency |
| US20050239733A1 (en) | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
| US20050100983A1 (en) | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
| KR100558851B1 (ko) | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체 |
| JP2007526253A (ja) | 2004-02-19 | 2007-09-13 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 免疫刺激性ウイルスｒｎａオリゴヌクレオチド |
| JP2007531746A (ja) | 2004-04-02 | 2007-11-08 | コーリー ファーマシューティカル グループ，インコーポレイテッド | Ｉｌ−１０応答を誘導するための免疫活性化核酸 |
| US20080113929A1 (en) | 2004-06-08 | 2008-05-15 | Coley Pharmaceutical Gmbh | Abasic Oligonucleotide as Carrier Platform for Antigen and Immunostimulatory Agonist and Antagonist |
| EP1776105A2 (de) | 2004-07-18 | 2007-04-25 | Coley Pharmaceutical Group, Ltd | Verfahren und zusammensetzungen zur induzierung eigener immunantworten |
| US20060287263A1 (en) | 2004-07-18 | 2006-12-21 | Csl Limited | Methods and compositions for inducing antigen-specific immune responses |
| MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| US20080009455A9 (en) | 2005-02-24 | 2008-01-10 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
| JP2008535859A (ja) | 2005-04-08 | 2008-09-04 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 感染症によって悪化した喘息を治療するための方法 |
| AU2006241149A1 (en) | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
| JP4538522B2 (ja) | 2005-11-25 | 2010-09-08 | コーリー ファーマシューティカル ゲーエムベーハー | 免疫刺激性オリゴリボヌクレオチド |
| MX2008008279A (es) | 2005-12-20 | 2009-03-04 | Idera Pharmaceuticals Inc | Actividad inmunoestimuladora de oligonucleotidos inmunoestimuladores palindromicos que contienen diferentes longitudes de segmentos palindromicos. |
| DK2405002T3 (en) | 2006-02-15 | 2015-01-05 | Adiutide Pharmaceuticals Gmbh | Compositions and methods for oligonukleotidformuleringer |
| US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
| WO2008033432A2 (en) | 2006-09-12 | 2008-03-20 | Coley Pharmaceutical Group, Inc. | Immune modulation by chemically modified ribonucleosides and oligoribonucleotides |
| MX2009003403A (es) | 2006-09-27 | 2009-04-09 | Coley Pharm Group Inc | Composiciones de ligandos de tlr y antivirales. |
| PT2078080E (pt) | 2006-09-27 | 2015-09-18 | Coley Pharm Gmbh | Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada |
| AU2007353120A1 (en) | 2006-10-26 | 2008-11-20 | Coley Pharmaceutical Gmbh | Oligoribonucleotides and uses thereof |
-
2002
- 2002-08-19 AT AT02768621T patent/ATE411054T1/de active
- 2002-08-19 AU AU2002331643A patent/AU2002331643B2/en not_active Ceased
- 2002-08-19 CN CN028182138A patent/CN1604795B/zh not_active Expired - Fee Related
- 2002-08-19 BR BR0211962-5A patent/BR0211962A/pt not_active Application Discontinuation
- 2002-08-19 EA EA200400319A patent/EA007232B1/ru not_active IP Right Cessation
- 2002-08-19 ES ES02768621T patent/ES2314099T3/es not_active Expired - Lifetime
- 2002-08-19 PT PT02768621T patent/PT1446162E/pt unknown
- 2002-08-19 IL IL16015702A patent/IL160157A0/xx unknown
- 2002-08-19 SG SG2006010128A patent/SG177000A1/en unknown
- 2002-08-19 NZ NZ552377A patent/NZ552377A/en not_active IP Right Cessation
- 2002-08-19 MX MXPA04001458A patent/MXPA04001458A/es active IP Right Grant
- 2002-08-19 KR KR1020047002289A patent/KR100991644B1/ko not_active Expired - Fee Related
- 2002-08-19 WO PCT/US2002/026468 patent/WO2003015711A2/en not_active Ceased
- 2002-08-19 DK DK02768621T patent/DK1446162T3/da active
- 2002-08-19 CA CA2457485A patent/CA2457485C/en not_active Expired - Lifetime
- 2002-08-19 US US10/224,523 patent/US8834900B2/en not_active Expired - Fee Related
- 2002-08-19 SI SI200230776T patent/SI1446162T1/sl unknown
- 2002-08-19 JP JP2003520672A patent/JP4383534B2/ja not_active Expired - Fee Related
- 2002-08-19 NZ NZ531194A patent/NZ531194A/en not_active IP Right Cessation
- 2002-08-19 EP EP02768621A patent/EP1446162B1/de not_active Expired - Lifetime
- 2002-08-19 DE DE60229422T patent/DE60229422D1/de not_active Expired - Lifetime
-
2004
- 2004-02-01 IL IL160157A patent/IL160157A/en unknown
- 2004-02-25 ZA ZA2004/01531A patent/ZA200401531B/en unknown
-
2008
- 2008-10-03 JP JP2008259120A patent/JP2009028051A/ja not_active Withdrawn
- 2008-12-03 CY CY20081101400T patent/CY1109398T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001055370A2 (en) * | 2000-01-26 | 2001-08-02 | Hybridon, Inc. | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
Non-Patent Citations (3)
| Title |
|---|
| HARTMANN G ET AL: "delineation of a CpG phosphorothioate oligodeoxynucleotide for activating promate immune responses in vitro and in vivo", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 164, no. 3, 1 February 2000 (2000-02-01), pages 1617 - 1624, XP002267233, ISSN: 0022-1767 * |
| KRIEG ARTHUR M ET AL: "Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, no. 21, 13 October 1998 (1998-10-13), pages 12631 - 12636, XP002161301, ISSN: 0027-8424 * |
| KRIEG ARTHUR M: "Now I know my CpGs", TRENDS IN MICROBIOLOGY, vol. 9, no. 6, June 2001 (2001-06-01), pages 249 - 252, XP002310311, ISSN: 0966-842X * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1446162A4 (de) | Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung | |
| CY1107351T1 (el) | Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης | |
| DE69941059D1 (de) | Nukleotid- und proteinsequenzen von nogo-genen und darauf beruhende methoden | |
| CY1105475T1 (el) | Συνθεσεις και μεθοδοι θepαπευτικης αγωγης νεοπλασματων | |
| EP1417351A4 (de) | Antisense-modulation der expression von apolipoprotein(a) | |
| EP1419168A4 (de) | Antisense-modulation der expression von apolipoprotein b | |
| EP1417216A4 (de) | Antisense-modulation der bcl2 assoziierten x-protein-expression | |
| ATE310089T1 (de) | Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen | |
| EP1409509A4 (de) | Antisense-modulation der expression von c-reactive-protein | |
| CY1108240T1 (el) | ΑΠΟΜΟΝΩΜΕΝΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΤΑ ΟΠΟΙΑ ΕΧΟΥΝ ΕΝΑ ΜΕΙΩΜΕΝΟ ΠΕΡΙΕΧΟΜΕΝΟ ΜΟΤΙΒΩΝ 5΄CpG3΄ ΕΠΙΓΕΝΕΤΙΚΟΥ ΕΛΕΓΧΟΥ ΚΑΙ ΟΙ ΧΡΗΣΕΙΣ ΤΟΥΣ | |
| WO2003022222A3 (en) | Antisense modulation of protein kinase r expression | |
| EP1131107A4 (de) | Antisense-modulation der expression von inhibitor-kappa-b-kinase-alpha | |
| DE69833876D1 (de) | Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren | |
| NO20010940L (no) | TAN-1057 derivater | |
| EP1248795A4 (de) | Antisens-modulierung der expression des makrophagenmigrationshemmenden faktors | |
| MX9805158A (es) | Adn que codifica una proteina activadora de plasminogeno. | |
| DE60135232D1 (de) | Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen | |
| EP1441740A4 (de) | Antisense-modulation der matrix-metalloproteinase-1-expression | |
| WO2002020716A3 (en) | Antisense modulation of phosphorylase kinase alpha 2 expression | |
| WO2001075022A3 (fr) | Nouveau polypeptide, eucaryon acetyl transferase humaine 12, et polynucleotide codant pour ce polypeptide | |
| WO2001075026A3 (fr) | Nouveau polypeptide, eucaryote acetyl transferase humaine 10, et polynucleotide codant pour ce polypeptide | |
| WO2001075046A3 (fr) | Nouveau polypeptide, gene humain de regulation 17 du cycle mitotique, et polynucleotide codant pour ce polypeptide | |
| FR2812656B1 (fr) | Acides nucleiques et proteines d'e. coli pathogenes, et leurs utilisations | |
| WO2001094540A3 (en) | A novel polypeptide, a human glucosyl hydrolase 23 and the polynucleotide encoding the polypeptide | |
| WO2001075002A3 (fr) | Nouveau polypeptide, gène de regulation du cycle cellulaire humain 28, et polynucléotide codant pour ce polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20040317 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20050103 |
|
| RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20050114 |
|
| 17Q | First examination report despatched |
Effective date: 20050223 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1067547 Country of ref document: HK |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UNIVERSITY OF IOWA RESEARCH FOUNDATION Owner name: COLEY PHARMACEUTICAL GMBH |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: UHLMANN, EUGEN Inventor name: KRIEG, ARTHUR, M. Inventor name: VOLLMER, JOERG |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UNIVERSITY OF IOWA RESEARCH FOUNDATION Owner name: COLEY PHARMACEUTICAL GMBH |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV RO SI |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REF | Corresponds to: |
Ref document number: 60229422 Country of ref document: DE Date of ref document: 20081127 Kind code of ref document: P |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: MOINAS & SAVOYE SA |
|
| REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20080403463 Country of ref document: GR |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20090115 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2314099 Country of ref document: ES Kind code of ref document: T3 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1067547 Country of ref document: HK |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20090716 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: COLEY PHARMACEUTICAL GMBH, US Free format text: FORMER OWNER: COLEY PHARMACEUTICAL GMBH, US |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20200826 Year of fee payment: 19 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20200804 Year of fee payment: 19 Ref country code: DE Payment date: 20200827 Year of fee payment: 19 Ref country code: FI Payment date: 20200827 Year of fee payment: 19 Ref country code: ES Payment date: 20200901 Year of fee payment: 19 Ref country code: EE Payment date: 20200804 Year of fee payment: 19 Ref country code: LU Payment date: 20200827 Year of fee payment: 19 Ref country code: CY Payment date: 20200805 Year of fee payment: 19 Ref country code: IE Payment date: 20200827 Year of fee payment: 19 Ref country code: DK Payment date: 20200827 Year of fee payment: 19 Ref country code: CZ Payment date: 20200806 Year of fee payment: 19 Ref country code: GR Payment date: 20200826 Year of fee payment: 19 Ref country code: FR Payment date: 20200825 Year of fee payment: 19 Ref country code: GB Payment date: 20200827 Year of fee payment: 19 Ref country code: PT Payment date: 20200804 Year of fee payment: 19 Ref country code: TR Payment date: 20200807 Year of fee payment: 19 Ref country code: SK Payment date: 20200731 Year of fee payment: 19 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20200827 Year of fee payment: 19 Ref country code: BE Payment date: 20200827 Year of fee payment: 19 Ref country code: CH Payment date: 20200903 Year of fee payment: 19 Ref country code: BG Payment date: 20200824 Year of fee payment: 19 Ref country code: AT Payment date: 20200803 Year of fee payment: 19 Ref country code: IT Payment date: 20200821 Year of fee payment: 19 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60229422 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20210831 |
|
| REG | Reference to a national code |
Ref country code: FI Ref legal event code: MAE |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20210901 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 411054 Country of ref document: AT Kind code of ref document: T Effective date: 20210819 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210831 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20210819 |
|
| REG | Reference to a national code |
Ref country code: SK Ref legal event code: MM4A Ref document number: E 4967 Country of ref document: SK Effective date: 20210819 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210819 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 Ref country code: BG Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220228 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210819 |
|
| REG | Reference to a national code |
Ref country code: SI Ref legal event code: KO00 Effective date: 20220406 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210820 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220221 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210819 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220308 Ref country code: CZ Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210819 Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210819 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210901 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210819 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210819 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210819 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210819 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220301 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20220929 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20220830 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210820 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210831 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210819 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210819 |